In a report released today, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Geron (GERN – Research Report), with a price target ...
Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug delivery technology, announced that Serina Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback